Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer
Phase: PHASE2
Conditions: Breast Cancer
Sponsor: M.D. Anderson Cancer Center

 
MDACC# 2010-0794 
Version Date: 6.13.17 
COVER PAGE 
MDACC #: 
2010-0794 
Phase II Short-term Adjuvant Therapy and Biomarker studies with targeted agents in Women 
with Estrogen Receptor Negative Breast Cancer 
Principal Investigators: 
Banu Arun, M.D. 
The University of Texas M.D. Anderson Cancer Center 
Telephone: 713-792-2817 
Fax: 713-563-0910 
E-mail address: barun@mdanderson.org 
Victoria Seewaldt, M.D. 
Duke University 
Telephone: 919-668-2454 
E-mail address: seewa001@mc.duke.edu 
Dihua Yu, M.D. 
The University of Texas M.D. Anderson Cancer Center 
Telephone: 713-792-3636 
E-mail address: dyu@mdanderson.org 
Collaborators: 
Yun Gong, M.D. 
The University of Texas M.D. Anderson Cancer Center 
Telephone: 713 563 5625 
Fax: 713 563 5664 
E-mail address: ygong@mdanderson.org 
Neil Spector, M.D. 
Duke University 
Telephone: 919 681 4699 
Statistician: 
Diane D Liu. 
The University of Texas M.D. Anderson Cancer Center 
Telephone: 713-794-4175 
Fax: 713-563-4242 
E-mail address: dliu@mdanderson.org 
Proprietary Information of MD Anderson

ii 
 
 
MDACC# 2010-0794 
Version Date: 6.13.17 
 
 
 
SCHEMA 
 
 
Phase II Short-term Adjuvant Therapy and Biomarker studies with targeted agents in Women with 
Estrogen Receptor Negative Breast Cancer 
 
 
Study Population: Women history of ER negative breast cancer 
 
 
 
 
Medical history, (physical exam), blood 
 
 
 
 
Sign consent 
 
 
 
 
Baseline random periareolar breast fine needle aspiration (RPFNA), research blood 
 
 
 
 
 
Randomize, on study for 3 months (+/- 7 days) 
 
Month 3 periareolar breast fine needle aspiration, research blood 
Endpoints: Primary: Changes in Ki-67 
Secondary: Changes in cytology, proliferation, apoptosis in breast tissue (p-Y418-Src, p-Y-118- 
Paxillin, (and markers identified in Aims 1 and 3 of the grant), CC3, bcl-2, EGFR, P-EGFR, IGF 
pathway in serum) 
 
Toxicity assessment 
Proprietary Information of MD Anderson

 
 
 
MDACC# 2010-0794 
Version Date: 6.13.17 
 
 
 
TABLE OF CONTENTS 
 
Page 
COVER PAGE ............................................................................................................................................. i 
SCHEMA ..................................................................................................................................................... ii 
TABLE OF CONTENTS ........................................................................................................................... iii 
1. OBJECTIVES 
1.1 
Primary Objective ...................................................................................................................... 1 
1.2 
Secondary Objectives ................................................................................................................ 1 
2. BACKGROUND ................................................................................................................................... 1 
2.1 
Breast Cancer Chemoprevention and Chemoprevention Agents .............................................. 1 
2.2 
Dasatinib as Chemopreventive Agent for Breast Cancer .......................................................... 1 
2.3 
Tissue Acquisition Methods ...................................................................................................... 8 
3. SUMMARY OF STUDY PLAN 
8 
4. PARTICIPANT SELECTION ............................................................................................................ 9 
4.1 
Inclusion Criteria ....................................................................................................................... 9 
4.2 
Exclusion Criteria .................................................................................................................... 10 
4.3 
Inclusion of Women and Minorities ........................................................................................ 11 
4.4 
Recruitment and Retention Plan .............................................................................................. 11 
5. AGENT ADMINISTRATION 
5.1 
Dose Regimen and Dose Groups ............................................................................................ 12 
5.2 
Study Agent Administration ................................................................................................... 12 
5.3 
Run-In Procedures .................................................................................................................. 12 
5.4 
Prohibited Therapies ............................................................................................................... 12 
5.5 
Restricted Therapies ................................................................................................................ 13 
5.6 
Concomitant Medications ....................................................................................................... 14 
5.7 
Dose Modifications ................................................................................................................. 14 
5.8 
Adherence/Compliance ........................................................................................................... 14 
6. PHARMACEUTICAL INFORMATION ......................................................................................... 15 
6.1 
Study Agent ............................................................................................................................. 15 
6.2 
Rationale for Dose Selection ................................................................................................... 16 
6.3 
Availability .............................................................................................................................. 16 
6.4 
Agent Accountability .............................................................................................................. 16 
6.5 
Packaging and Labeling .......................................................................................................... 17 
6.6 
Storage .................................................................................................................................... 17 
6.7 
Registration / Randomization .................................................................................................. 17 
6.8 
Registration / Randomization .................................................................................................. 17 
6.9 
Blinding and Unblinding Methods .......................................................................................... 18 
6.10 
Agent Destruction/Disposal ..................................................................................................... 18 
7. CLINICAL EVALUATIONS AND PROCEDURES 
7.1 
Schedule of Events ................................................................................................................... 18 
7.2 
Baseline Testing/Prestudy Evaluation ....................................................................................... 18 
7.3 
Evaluation During Study Intervention ...................................................................................... 19 
Proprietary Information of MD Anderson

 
 
 
MDACC# 2010-0794 
Version Date: 6.13.17 
 
7.4 
Evaluation at Completion of Intervention ................................................................................. 19 
7.5 
Methods for Clinical Procedures ............................................................................................... 19 
8. CRITERIA FOR EVALUATION AND ENDPOINT DEFINITION ............................................ 24 
8.1 
Primary Endpoint  ................................................................................................................... 24 
8.2 
Secondary Endpoints  .............................................................................................................. 24 
8.3 
Off Agent Criteria ................................................................................................................... 24 
8.4 
Off Study Criteria  ................................................................................................................... 24 
9. SPECIMEN MANAGEMENT  ......................................................................................................... 25 
9.1 
Laboratories  ............................................................................................................................ 25 
9.2 
Collection and handling procedures  ....................................................................................... 25 
9.3 
Tissue Banking  ....................................................................................................................... 26 
10. REPORTING ADVERSE EVENTS  ................................................................................................ 26 
10.1 
Adverse Events  ........................................................................................................................ 26 
10.2 
Serious Adverse Events  ........................................................................................................... 27 
11. STUDY MONITORING  ................................................................................................................... 28 
12. STATISTICAL CONSIDERATIONS  ............................................................................................. 28 
13. ETHICAL AND REGULATORY CONSIDERATIONS  ............................................................... 30 
13.1 
Form FDA 1572 ....................................................................................................................... 30 
13.2 
Other Required Documents  ..................................................................................................... 30 
13.3 
Institutional Review Board Approval  ...................................................................................... 30 
13.4 
Informed Consent  .................................................................................................................... 31 
13.5 
Other  ........................................................................................................................................ 31 
REFERENCES  ......................................................................................................................................... 32 
Proprietary Information of MD Anderson

1  
 
 
M D A C C # 2 0 1 0 -0 7 9 4  
 
 
V ersi o n D at e: 6. 1 3 . 1 7 
 
 
1.  O B J E C T I VE S  
 
 
O verall o b j ecti ve is t o eval uate t he c hem o pre v e nti ve p ote ntial of dasatin i b i n a ph ase II s h ort term 
a dj u va nt a n d bi omar k er st u d y, b y e val uati n g its bi o mar ker m o d ulat or y efficac y i n breast tiss ue a n d seru m 
of w o m e n at  inc rease d ris k f or sec on d p ri mar y brea st ca ncer. 
 
1. 1.  Pri mar y O bj ec tive 
 
T o e val ua te t he a bilit y of treatm e nt wi t h dail y dasa ti ni b t o decrease pr oliferati o n of hi g h r is k br east 
e pit helial cells o n c on tralateral ra n d o m periare ola r fi ne need le asp irati o n ( R P F N A) i n patien ts wit h 
brea st ca ncer t hat d o n ot o ver e xpre ss estr oge n re cep t or (E R ). We wi ll e val uate pre- a n d p ost dasat i ni b 
treat me nt Ki - 6 7 i n sa mples  o btai ne d via F N A fr o m breast tiss ue of w o m e n at hi g h ris k  f or sec o n d 
pri mar y brea st ca ncer. T his s pecific ai m tests t he h y p ot hesis t hat treat me nt wit h dasati ni b will i n d uce a 
decr ease i n pr oliferati o n. 
 
1. 2.  Sec o n dar y O bj ec tives: 
 
 
1)  T o e val uate dasati n i b in d uce d m o d ula ti o n of c yt ol og y , ot her pr oliferati o n an d a p o pt osi s mar kers i n 
hi g h ris k  breast tiss ue ( p- Y 4 1 8-Src, p - Y- 1 1 8-Pa xill i n, e pi der mal gr ow t h fact or rece pt or ( E G F R), 
p h os p h or y late d E GF R  ( P- E G F R), b cell l y m p h o ma 2 ( bcl- 2), clea ve d cas pase 3 ( C C3,)) b y 
i m m u n o hist oc he mistr y (I H C) a n d b y direct pr ote om ic pr ofili n g met h o ds (as well as n o vel  mar kers 
i de ntifie d i n Ai ms 1 a n d 3 of t h e g ra nt: I G F- 1, I GF B P 1 a n d 3 ). 
 
2)  T o e val uat e dasati ni b in d uce d m o d ula ti o n of b i omar k er i n t he seru m  i nclu di n g ins u li n li ke g r owt h 
fact or (I G F) pat h wa y 
 
3)  T o a ssess t o xicit y of da sati ni b i n t his patie nt p o p ulati o n 
 
2.  B A C K G R O U N D A N D R A TI O N A L E  
 
2. 1 Bre ast  Ca ncer  Che m o pre ve nt io n a n d C he m o pr e vent io n A g e nts 
 
Ta m o xife n i s curr e ntl y t he o nl y F D A a p pr o ve d a ge nt f or t he pre ve nti o n of breast ca ncer in hi g h ris k 
w o m e n ( 1). T he Na ti on al A dj u va nt Breast a n d B o wel Pr oj e ct ( N S AB P ) c o n d ucted a lar ge-scale, d o u ble 
bli n d, p ha se III breast  ca ncer pre ve nti o n trial P1 ( B C P T- P 1) usi n g tam o xi fe n vers us pl aceb o i n  1 3, 3 8 8 
w o m e n at  hi gh r is k f or b reast ca ncer (2 ). Af ter a m e dia n f oll o w- u p of 5 4 m o nt hs, a 4 9 % red uc ti o n i n t he 
i nci de nce o f i nvasi v e breast ca ncer ( p 0. 0 0 0 0 1 ) occ urre d a mo n g  t h ose recei vi n g tam o xife n ( 1 ).  Si de 
effects see n wit h tam o xife n use inc lu de d  i ncrease d ris k of t hr om b oe m b olic e v e nts, uterin e cance r, a n d 
me n o pa usal s ym pt o ms. F urt her m ore, re ducti o n s ee n i n breast ca ncer i nci den ce wa s o nl y i n E R p ositiv e 
t um ors;  ta mo xife n  di d n ot  re d uce t he i nci dence o f E R ne gati ve breast canc er. E R ne gati ve breast canc ers 
occ ur m ore i n pre- me n o pa usal  w o me n a n d are associat e d wi th a g g ressi ve beha vi or a n d p o or p r og n os tic 
feat ures (3 ), (4 ). U nf ortu n atel y, c urren tl y t here are n o n o n- h or m o nal a g e nts a vaila ble a n d a p pr ov e d f or  
t he prev e nti o n o f E R ne gativ e ca ncer. F urt her more, t here is a n ee d f or less t o xic ag e nts. Se veral c lasses o f 
c om m o nl y use d dr u g s a n d n o vel a ge nts, s uc h as N S AI D s, reti no i ds, ornit hi n e decar b o x ylase i n hi bit ors, 3- 
h y dr o x y- 3- met h yl g l utar yl c oe nz y me A ( H M G- C o A) re d ucta se i nh i bit ors (stati ns), a n d src in hi bi t or, are 
p ote nti al a ge nts f or i nv esti gatio n f o r b reast ca ncer prev e nti o n
Pr o pri et ar y I nf or m ati o n of M D A n d er s o n

2 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
2.2   Dasatinib as a Chemopreventive Agent for Breast Cancer 
Preclinical studies: 
 
The steroid receptor co-activator (Src) pathway shares a common pathway with AMPK via mammalian 
target of rapamycin (mTOR). c-Src (Src) belongs to the Src family non-receptor tyrosine kinases. All Src 
family members share structural similarities: 1) a c-terminal tail containing a negative-regulatory Y residue 
(Y527); 2) Src homology domains (SH2 and SH3) and SH1 kinase domain containing an 
autophosphorylation site (Y416) for maximal kinase activity; and 3) a N-terminal domain (SH4) for 
myrisylation and membrane binding (5). EGFR and HER2, similar to other growth factor receptors, can 
bind to and activate Src (6). Src is involved in multiple tumorigenesis processes (7).  Src overexpression 
(Src+) and activation was detected in > 80% of ductal carcinoma in situ (DCIS) lesions and correlated with 
HER2 expression (7), (8).   In our preliminary data, Src+ and activation was detected in 10% (1/10) 
patients with breast hyperplasia, 50% (3/6) patients with high-grade atypia, 80% (4/5) patients with ER- 
high grade atypia. Src+ also correlated with HER2+, and Src phosphorylation on Y416 (p-Y-416, 
indicating activation) predicted ER negativity/Tamoxifen resistance (TamR). The reverse relationship 
between Src and ER is consistent with previous reports that Src promoted estrogen dependent ERalpha 
degradation (9).  Src activation has also been observed in TamR breast cancer cells and Src inhibitor 
(AZD0530) suppressed the invasion of TamR cells (10). These findings highlight a key role for Src in 
receptor tyrosine kinase (RTK) signaling, and in ER- breast cancer development. Therefore, inhibiting src 
pathway may present an effective way to prevent breast cancer. 
 
Dasatinib is a potent, broad spectrum ATP-competitive inhibitor of 5 critical oncogenic tyrosine 
kinase/kinase families: BCR-ABL, SRC, c-KIT, PDGF receptor β (PDGFRβ), and ephrin (EPH) receptor 
kinases, each of which has been linked to multiple forms of human malignancies. Drug discovery and 
nonclinical pharmacology studies showed that dasatinib (Sprycel (dasatinib) BMS-354825 B-MSIB, version 
#5, 2006) inhibit proliferation of cancer cell lines that express activated src and c-kit. 
 
 
Clinical Experience with dasatinib: 
 
Four single-arm multicenter studies were conducted to determine the efficacy and safety of dasatinib in 
patients with CML or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) resistant 
to or intolerant of treatment with imatinib. Resistance to imatinib included failure to achieve a complete 
hematologic response (within 3–6 months) or major cytogenetic response (by month 12) or progression 
of disease after a previous cytogenetic or hematologic response. Imatinib intolerance included inability to 
tolerate 400 mg or more of imatinib per day or discontinuation of imatinib because of toxicity. The studies 
are ongoing. The results are based on a minimum of 6 months follow-up after the start of dasatinib 
therapy. Most patients had long disease histories with extensive prior treatment, including imatinib, 
cytotoxic chemotherapy, interferon, and stem cell transplant. The maximum imatinib dose had been 400–
600 mg/day in about one-half of the patients and >600 mg/day in the other half (SPRYCEL® (dasatinib) 
Tablets Prescribing Information.Bristol-Myers Squibb Company P, NJ. June 2006). All patients were treated 
with dasatinib 70 mg BID on a continuous basis. The median durations of treatment was between 2.8 
- 5.6 months SPRYCEL® (dasatinib) Tablets Prescribing Information. Bristol-Myers Squibb Company P, 
NJ. June 2006). 
 
The primary efficacy endpoint in chronic phase CML was major cytogenetic response (MCyR), defined as 
elimination (complete cytogenetic response, CCyR) or substantial diminution (by at least 65%, partial 
cytogenetic response) of Ph+ hematopoietic cells. The primary endpoint in accelerated phase, myeloid 
blast phase, and lymphoid blast phase CML, and Ph+ ALL was major hematologic response (MaHR), 
defined as either a complete hematologic response or no evidence of leukemia as defined in Table 1. 
Proprietary Information of MD Anderson

3 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
 
Most cytogenetic responses occurred after 12 weeks of treatment, when the first cytogenetic analyses 
were performed. Hematologic and cytogenetic responses were stable during the 6-month follow-up of 
patients with chronic phase, accelerated phase, and myeloid blast phase CML. The median durations of 
major hematologic response were 3.7 months in lymphoid blast CML and 4.8 months in Ph+ ALL. There 
were no age- or gender-related response differences (SPRYCEL® (dasatinib) Tablets Prescribing 
Information.  Bristol-Myers Squibb Company P, NJ. June 2006) 
 
Table 1: 
Efficacy in Dasatinib Clinical Studies (All Treated Populations)a 
Chronic 
(n=186) 
Accelerated 
(n=107) 
Myeloid 
Blast 
(n=74) 
Lymphoid 
Blast 
(n=42) 
Ph+ ALL 
(n=36) 
Hematologic Response Rateb (%) 
MaHR (95% CI) 
n/a 
59 (49–68) 
32 (22–44) 
31 (18–47) 
42 (26–59) 
CHR (95% CI) 
90 (85–94) 
33 (24–42) 
24 (15–36) 
26 (14-42) 
31 (16–48) 
NEL (95% CI) 
n/a 
26 (18–36) 
8 (3–17) 
5 (0.6–16) 
11 (3.1–26) 
Cytogenetic Responsec (%) 
MCyR (95% CI) 
45 (37–52) 
31 (22–41) 
30 (20–42) 
50 (34–66) 
58 (41–74) 
CCyR (95% CI) 
33 (26–40) 
21 (14–30) 
27 (17–39) 
43 (28–59) 
58 (41–74) 
a Numbers in bold font are the results of primary endpoint. 
b Hematologic response criteria (all responses confirmed after 4 weeks): 
Major hematologic response: (MaHR) = complete hematologic response (CHR) + no evidence of 
leukemia (NEL). 
CHR (chronic CML): WBC ≤ institutional ULN, platelets <450,000/mm3, no blasts or 
promyelocytes in peripheral blood, <5% myelocytes plus metamyelocytes in peripheral blood, 
basophils in peripheral blood ≤ institutional ULN, and no extramedullary involvement. 
CHR (advanced CML/Ph+ ALL):  WBC ≤ institutional ULN, ANC ≥ 1000/mm3, 
platelets ≥ 100,000/mm3, no blasts or promyelocytes in peripheral blood, bone marrow 
blasts ≤ 5%, <5% myelocytes plus metamyelocytes in peripheral blood, basophils in 
peripheral blood ≤ institutional ULN, and no extramedullary involvement. 
NEL: same criteria as for CHR but ANC ≥ 500/mm3, <1000/mm3 and/or platelets ≥ 20,000/mm3 
and ≤ 100,000/mm3. 
c Cytogenetic response criteria: complete (0% Ph+ metaphases) or partial (>0%–35%). MCyR (0%– 
35%) combines both complete and partial responses. 
n/a = not applicable. 
 
Safety of dasatinib in clinical studies 
 
The below data reflect exposure to dasatinib in 911 patients with leukemia from 1 Phase I and 5 Phase II 
clinical studies. The median duration of therapy was 6 months (range 0–19 months). 
 
The majority of dasatinib -treated patients experienced adverse drug reactions at some time. Drug was 
discontinued for adverse drug reactions in 6% of patients in chronic phase CML, 5% in accelerated phase 
CML, 11% in myeloid blast phase CML, and 6% in lymphoid blast phase CML or Ph+ ALL. 
 
The most frequently reported serious adverse events (SAEs) included pyrexia (9%), pleural effusion 
(8%), febrile neutropenia (7%), gastrointestinal bleeding (6%), pneumonia (6%), thrombocytopenia (5%), 
dyspnea (4%), anemia (3%), cardiac failure (3%), and diarrhea (2%). 
Proprietary Information of MD Anderson

4 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
 
All treatment-emergent adverse events (excluding laboratory abnormalities), regardless of relationship to 
study drug, that were reported in at least 20% of the patients in dasatinib clinical studies are shown in 
Table 2. 
 
Table 2: 
Adverse Events Reported ≥ 20% in Clinical Studies 
All Patients 
(n=911) 
All 
Grades 
Grades 
 3/4 
Chronic 
Phase 
(n=488) 
Grades 3/4 
Accelerate 
d Phase 
(n=186) 
Grades 
3/4 
Myeloid 
Blast 
Phase 
(n=132) 
Grades 
3/4 
Lymphoid 
Blast Phase 
and 
Ph+ ALL 
(n=105) 
Grades 3/4 
Preferred Term 
Percent (%) of Patients 
Fluid Retention 
50 
9 
6 
6 
23 
9 
Superficial Edema 
36 
1 
0 
2 
3 
2 
Pleural Effusion 
22 
5 
3 
3 
14 
8 
Diarrhea 
49 
5 
3 
10 
8 
6 
Headache 
40 
2 
2 
2 
4 
6 
Hemorrhage 
40 
10 
3 
18 
23 
17 
Musculoskeletal Pain 
39 
4 
2 
3 
6 
13 
Pyrexia 
39 
5 
1 
5 
13 
9 
Fatigue 
39 
3 
2 
4 
4 
8 
Skin Rasha 
35 
1 
1 
1 
1 
4 
Nausea 
34 
1 
<1 
0 
5 
2 
Dyspnea 
32 
6 
5 
7 
11 
9 
Cough 
28 
<1 
<1 
1 
1 
0 
Infection (including 
bacterial, viral, fungal, 
non-specified) 
34 
7 
4 
8 
15 
13 
Infection/Inflammat 
ion 
26 
1 
1 
1 
5 
1 
Abdominal Pain 
25 
2 
1 
2 
4 
6 
Pain 
26 
2 
<1 
1 
5 
4 
Vomiting 
22 
1 
1 
2 
2 
2 
Febrile Neutropenia 
9 
8 
2 
11 
17 
20 
Proprietary Information of MD Anderson

5 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
Myelosuppression was commonly reported in all patient populations. The frequency of Grade 3 or 4 
neutropenia, thrombocytopenia, and anemia was higher in patients with advanced CML or Ph+ ALL than 
in chronic phase CML. Myelosuppression was reported in patients with normal baseline laboratory values 
as well as in patients with pre-existing laboratory abnormalities (Table 3). 
 
In patients who experienced severe myelosuppression, recovery generally occurred following dose 
interruption and/or reduction; permanent discontinuation of treatment occurred in 1% of patients. Grade 3 
or 4 elevations of transaminases or bilirubin and Grade 3 or 4 hypocalcemia and hypophosphatemia 
were reported in patients with all phases of CML but were reported with an increased frequency in patients 
with myeloid or lymphoid blast CML and Ph+ ALL. Elevations in transaminases or bilirubin were usually 
managed with dose reduction or interruption. Patients developing Grade 3 or 4 hypocalcemia during the 
course of dasatinib therapy often had recovery with oral calcium supplementation. (Table 3). 
 
Table 3: 
CTC Grades 3/4 Laboratory Abnormalities in Clinical Studies 
Chronic 
Phase 
 
(n=488)  
Accelerated 
Phase 
(n=186)  
Myeloid 
Blast Phase 
(n=132)  
Lymphoid 
Blast Phase 
and 
Ph+ ALL 
(n=105)  
 
Percent (%) of Patients 
Hematology Parameters 
Neutropenia 
49 
74 
83 
81 
Thrombocytopenia 
48 
83 
82 
83 
Anemia 
18 
70 
70 
51 
Biochemistry Parameters 
Hypophosphatemia 
11 
13 
23 
21 
Hypocalcemia 
2 
9 
20 
15 
Elevated SGPT (ALT) 
1 
4 
7 
11 
Elevated SGOT (AST) 
1 
2 
5 
8 
Elevated Bilirubin 
<1 
1 
5 
8 
Elevated Creatinine 
0 
2 
1 
1 
CTC   grades:   neutropenia   (Grade   3   ≥0.5–1.0   ×   109/L,   Grade   4   <0.5   ×   109/L); 
thrombocytopenia (Grade 3 ≥10–50 × 109/L, Grade 4 <10 × 109/L); anemia (hemoglobin 
≥65–80 g/L, Grade 4 <65 g/L); elevated creatinine (Grade 3 >3–6 × upper limit normal 
range (ULN), Grade 4 >6 × ULN); elevated bilirubin (Grade 3 >3–10 × ULN, Grade 4 >10 
×  ULN);  elevated  SGOT  or  SGPT  (Grade  3  >5–20  ×  ULN,  Grade 4  >20  ×  ULN); 
hypocalcemia (Grade 3 <7.0–6.0 mg/dL, Grade 4 <6.0 mg/dL); hypophosphatemia (Grade 3 
<2.0–1.0 mg/dL, Grade 4 <1.0 mg/dL). 
 
Myelosuppression 
Treatment with dasatinib B is associated with severe (NCI CTC Grade 3 or 4) thrombocytopenia, 
neutropenia, and anemia. Their occurrence is more frequent in patients with advanced CML or Ph+ ALL 
than in chronic phase CML. Complete blood counts should be performed weekly for the first 2 months 
and then monthly thereafter, or as clinically indicated. Myelosuppression was generally reversible and 
usually managed by withholding dasatinib temporarily or dose reduction (SPRYCEL® (dasatinib) Tablets 
Prescribing Information.  Bristol-Myers Squibb Company P, NJ. June 2006.). 
 
Proprietary Information of MD Anderson

6 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
In addition to causing thrombocytopenia in human subjects, dasatinib caused platelet dysfunction in vitro. 
Severe CNS hemorrhages, including fatalities, occurred in 1% of patients receiving dasatinib. Severe 
gastrointestinal hemorrhage occurred in 7% of patients and generally required treatment interruptions and 
transfusions. Other cases of severe hemorrhage occurred in 4% of patients. Most bleeding events were 
associated with severe thrombocytopenia. 
 
Patients were excluded from participation in dasatinib clinical studies if they took medications that inhibit 
platelet function or anticoagulants. Caution should be exercised if patients are required to take 
medications that inhibit platelet function or anticoagulants. 
 
Fluid Retention 
 
Dasatinib is associated with fluid retention, which was severe in 9% of patients, including pleural and 
pericardial effusion reported in 5% and 1% of patients, respectively. Severe ascites and generalized 
edema were each reported in 1%. Severe pulmonary edema was reported in 1% of patients. Patients who 
develop symptoms suggestive of pleural effusion such as dyspnea or dry cough should be evaluated by 
chest X-ray. Severe pleural effusion may require thoracentesis and oxygen therapy. Fluid retention 
events were typically managed by supportive care measures that include diuretics or short courses of 
steroids SPRYCEL® (dasatinib) Tablets Prescribing Information. Bristol-Myers Squibb Company P, NJ. 
June 2006. 
 
QT Prolongation 
 
In vitro data suggest that dasatinib has the potential to prolong cardiac ventricular repolarization (QT 
interval). In single-arm clinical studies in patients with leukemia treated with dasatinib, the mean QTc 
interval changes from baseline using Fridericia’s method (QTcF) were 3–6 msec; the upper 95% 
confidence intervals for all mean changes from baseline were <8 msec. Nine patients had QTc 
prolongation reported as an adverse event. Three patients (<1%) experienced a QTcF >500 msec. 
 
Dasatinib should be administered with caution to patients who have or may develop prolongation of QTc. 
These include patients with hypokalemia or hypomagnesemia, patients with congenital long QT 
syndrome, patients taking anti-arrhythmic medicines or other medicinal products that lead to QT 
prolongation, and cumulative high-dose anthracycline therapy. Hypokalemia or hypomagnesemia should 
be corrected prior to dasatinib administration (SPRYCEL® (dasatinib) Tablets Prescribing Information. 
Bristol-Myers Squibb Company P, NJ. June 2006). 
 
Phase I experience in Solid Tumors 
 
In a Phase I study (CA180003) conducted by Bristol Myers Squibb (BMS), dasatinib was administered on 
a BID schedule to 42 subjects with refractory solid tumor. To date, doses up to 160 mg BID on a 5-day 
on/2-day off schedule have been administered. A dose of 120 mg BID continuous daily schedule is 
currently under investigation. 
 
No severe clinical toxicity has been encountered. Gastrointestinal symptoms were reported in most 
subjects, fatigue was reported in 17 subjects (40%) and rash in 10 subjects (24%). Edema, lethargy and 
headache were uncommon, and appear to be dose-related. Grade 3 asymptomatic hypocalcemia was 
considered dose-limiting in one subject, Grade 2 rash was considered dose-limiting in two other subjects, 
and Grade 2 nausea and vomiting (with dysarthria, lightheadedness and lethargy in a 49 kg subject taking 
concurrent diazepam) was considered dose-limiting in one subject. 
 
In another Phase I study (CA180021), dasatinib was administered on a QD schedule to 24 subjects at 
doses up to 180 mg. Pleural effusions were observed in three subjects at the 180 mg dose level (one with 
pneumonia and two with malignant effusion). A dose of 250 mg QD is currently under consideration. 
Hypocalcemia, GI symptoms and skin rash have been mild and infrequent. 
 
To date, the safety profile in solid tumor subjects has been similar to that in CP CML subjects with the 
exception of severe myelosuppression, which has not been observed in solid tumor subjects and is 
considered related to efficacy against the leukemia as noted above, and severe bleeding which is secondary 
Proprietary Information of MD Anderson

7 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
to thrombocytopenia in most instances. 
 
2.3 Tissue Acquisition Method Fine Needle Aspiration of Breast Tissue and Biomarker Evaluation 
 
Intermediate biomarkers of cancer are phenotypic, genotypic, and molecular changes that occur during 
carcinogenesis. Currently there are no validated surrogate endpoint biomarkers for breast cancer in the 
context of chemoprevention trials with invasive cancer as the definitive end points; therefore the 
identification and validation of intermediate biomarkers as surrogate endpoints for subsequent large 
clinical chemoprevention trials for breast cancer is very important. In our current proposal, breast tissue 
and serum biomarker modulation that will reflect dasatinib activity will be evaluated. These will include, 
in breast tissue, cytologic changes, markers of proliferation, apoptosis and changes in proteomic profiling; 
in serum markers of IGF pathway (IGFBP1, IGFBP-3, IGF-I). 
 
Studies using periareolar fine needle aspiration (FNA) of the breast as a tissue acquisition method in 
phase I and II breast cancer prevention trials have been pioneered and successfully completed by Fabian 
et. al  (11) and is now considered to be an acceptable method, in early phase breast cancer prevention 
studies (12)  We have successfully used and are currently using this method in our prevention trials (13), 
(14). In our experience, this method is highly acceptable from the patient point of view, as all of our 
patients returned for their second FNAs and have not complained about the procedure. Therefore, we will 
use this method in our proposal. 
 
Conclusion and Clinical Relevance: 
 
Phase III breast cancer prevention trials require large numbers of patients, a long duration of follow-up, 
and are costly. As an alternative strategy, short-term chemoprevention trials utilizing surrogate markers of 
drug activity may allow for a small sample size and brief duration of exposure to assess the efficacy of 
potential chemopreventive agents. There is an immediate need to evaluate agents that can reduce the risk 
of ER negative breast cancer development. Finally, potential preventive agents should have a favorable 
safety profile. Taken all these and the preclinical information provided above, we are proposing a short- 
term phase II study evaluating the effects of dasatinib in women who are at increased risk to develop a 
second primary breast cancer. Our aim is to understand the pathway that is involved in ER negative breast 
cancer development and progression so that further studies with agents that target the src pathway 
(example p70S6K inhibitors) could be undertaken that will ultimately lead to the development of 
prospective phase III studies targeting ER negative breast cancer prevention. 
 
 
3. 
SUMMARY OF STUDY PLAN 
 
This is a phase II, prospective biomarker modulation study in women with a prior history of ER negative 
breast cancer who have currently no active disease and have completed all adjuvant therapy. Women with 
a previous history of breast cancer have a 0.5-0.8%/year risk to develop a contralateral primary breast 
cancer (15), (16) and hence represent a high risk study cohort.  Sixty six evaluable patients after signing 
informed consent will undergo baseline periareolar FNA of the breast and blood collection for the 
analysis of the proposed markers.  Participants will take no drug, or the study drug dasatinib at a dose of 
40mg or 80mg daily for 3 months (+/- 7 days) and at the end of the 3 months (+/- 7 days) will undergo a 
repeat FNA and blood collection for the same marker analyses. The study will be undertaken at the 
University of Texas, M.D. Anderson Cancer Center and Duke University. Patients will return to clinic at 
month 1 for evaluation and again at month 3 and will be followed-up with a phone call at month 2. 
Assuming a screening rate of approximately 20 participants per month and a conservatively estimated 
accrual rate of 2 patients per months we will be able to complete accrual in 30 months. 
Proprietary Information of MD Anderson

8 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
 
 
4. PARTICIPANT SELECTION 
 
4.1 Inclusion Criteria 
 
1. 
Histological confirmation of ER negative (defined as less than 10%) breast carcinoma, stage I, II, 
or III 
 
2. 
Completed all adjuvant therapy including (if indicated) endocrine, trastuzumab, radiation therapy. 
 
3. 
At least 18 years of age. 
 
4. 
Female: 
 
A female is eligible to enter and participate in the study if she is of: 
 
a. 
Non-childbearing potential (i.e., women with functioning ovaries who have a 
current documented tubal ligation, hysterectomy alone, hysterectomy and 
bilateral salpingo-oophorectomy, bilateral salpingo-oophorectomy alone, or 
women who are post-menopausal); or 
 
b. 
Childbearing potential (i.e., women with functioning ovaries and no documented impairment 
of oviductal or uterine function that would cause sterility.  This category includes women 
with oligomenorrhoea (severe), women who are perimenopausal, and young women who 
have begun to menstruate), has a negative urine or serum pregnancy test at screening, and 
agrees to one of the following where considered acceptable to the local IRB/IEC: 
 
• 
Double-barrier contraception (condom with spermicidal jelly, foam suppository, or 
film; diaphragm with spermicide; or male condom and diaphragm). 
 
• 
Abstinence from sexual intercourse from 2 weeks prior to administration of 
the investigational product, throughout the active study treatment period. 
 
• 
Male partner who is sterile prior to the female subject's entry into the study and is the 
sole sexual partner for that female subject. 
 
• 
Any intrauterine device (IUD). 
 
• 
Barrier methods including diaphragm or condom with a spermicide. 
 
5. 
Able to swallow and retain oral medication. 
 
6. 
ECOG (Eastern Cooperative Oncology Group) performance status 0 to 2. 
 
7. 
Provide written informed consent. 
 
8. 
Adequate bone marrow function 
• 
Hemoglobin ≥ 9 gm/dL. 
 
• 
Absolute granulocyte count ≥ 1,500/mm3 (1.5 x 109/L). 
 
• 
Platelets ≥ 75,000/mm3 (100 x 109/L). 
 
9. 
Serum creatinine < 1.4 mg/dL or calculated creatinine clearance (CrCl) ≥ 30 mL/min 
 
10. Total bilirubin ≤ 1.5 times the upper limit of the reference range 
 
11. Aspartate and alanine transaminase (AST or ALT) ≤ 2 times the upper limit of the reference range 
 
12.  Patients must have a baseline ECG with QTcF within the normal range within 28 days prior to 
registration. 
 
13.  Normal mammogram of unaffected breast within 12 months prior to study entry. 
Proprietary Information of MD Anderson

9 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
4.2 Exclusion Criteria 
 
 
1. Unwillingness to undergo RPFNA. 
 
2. Contraindication to RPFNA including breast implant(s), bilateral radiation, anticoagulation 
(excluding those on 81mg aspirin). 
 
3. Concurrent medical condition that would increase drug toxicity: Pleural or pericardial effusion, 
coagulation or platelet function disorder, ongoing or recent (less than 3 months gastrointestinal 
bleeding) 
 
4. Uncontrolled angina, congestive heart failure, MI (within last 6 months), congenital long QT 
syndrome, history of clinically significant ventricular arrhythmia, prolonged QTcF interval on 
pre- entry EKG (greater than normal range) 
 
5. Hypokalemia or hypomagnesemia if it cannot be corrected 
 
6. Is a pregnant or lactating female. 
 
7. Has evidence of recurrent or metastatic (Stage IV) breast cancer. 
 
8. Is considered medically unfit for the study by the investigator as a result of the medical 
interview, physical exam, or screening investigations. 
 
9. Has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to dasatinib 
 
10. Has received treatment with any investigational drug in the previous 4 weeks. 
 
11. Has received chemotherapy, immunotherapy, biologic therapy or endocrine therapy within the past 
12 weeks. 
 
12. Is currently receiving oral steroid treatment (inhaled steroids are permitted) 
 
13. Oral estrogen, progesterone, testosterone therapy within last 3 months. 
 
14. Concomitant Medications:  Drugs that are considered category D (Consider therapy modification) 
and X (Avoid combination) using the Lexicomp database are prohibited. Concomitant drugs that fall 
into categories A (No known interaction), B (no action needed) and C (monitor therapy) are allowed. 
 
4.3 Inclusion of Women and Minorities 
 
Since our research topic, breast cancer, is relevant to women, all of our participants will be women of all 
races and ethnic groups. Male breast cancer is seen very rarely, therefore, we will not include male 
participants. The research topic to be studied, breast cancer, mainly effects the adult population and is 
not relevant to children. Therefore, we will exclude individuals who are under 18 years of age. Our 
research proposal will study women who are at increased risk to develop a second primary breast 
cancer. 
 
4.4 Recruitment and Retention Plan 
 
Pre-initiation Recruitment 
During the pre-initiation recruitment phase, physicians within or outside the Institution working with 
patient populations that include potential participants will be contacted, the specific inclusion/exclusion 
Proprietary Information of MD Anderson

10 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
criteria reported, and the importance of accruing participants who are likely to be compliant and 
retainable will be emphasized. Contact with outside referring physicians will mainly take place by e- 
mail, and Newsletters, or by face-to-face meeting during outreach seminars, which is organized by the M. 
D. Anderson Physician Referral Service and the Physicians Network. Information about the study and 
eligibility criteria will be placed on our website. Investigators at each site will present the study to 
potential referring physicians within the Institution to explain the goals for the study, describe the 
protocol, discuss enrollment procedures, and provide contact information. Beside accrual from UT M.D. 
Anderson Cancer Center, a major source for minority referral for the study will be referrals from Lyndon 
B. Johnson (LBJ) Hospital, Houston, which primarily serves the minority and underserved population 
and is staffed by Faculty members from UT M.D. Anderson Cancer Center. A recent search of the LBJ 
Hospital database indicated that in the last 5 years, 42% of the patients who were seen at LBJ Hospital 
were African American and 28% were of Hispanic origin. We believe that LBJ Hospital will serve as an 
ideal referral source for minority accrual for our proposed study. 
 
UT M.D. Anderson Cancer Center recently opened a new center “Center for Research on Minority 
Health”. This center provides an opportunity for this trial to be publicized. Specifically, the PI will have 
an initial meeting with the Director of that Center, Dr. Jones, and brief him and his staff about the study 
and provide them with an eligibility summary card. Our study coordinator will then do bi-weekly 
follow- ups with that team to evaluate potential eligible participants. These can be done via e-mail or 
telephone. 
 
Other sources for minority recruitment will include working together with community and local 
organizations such as: Sisters' Network, Inc., One Hundred Black Women, National Association for the 
Advancement of Colored People, Inc., Top Ladies of Distinction, Inc. and the African Methodist 
Episcopal Church. We conservatively estimate that 10-15 % of the study participants will belong to the 
minority population. Besides these promising 5 community partnering programs, our program engages 
in a variety outreach programs, such as local churches, local shopping centers.  Brochures about the 
study will be taken to any events or functions the above mentioned organizations are doing. 
 
Active Recruitment Phase 
We have a very well developed web based communication system at UT MD Anderson Center which 
will assist us in posting newsletters and advertising the trial on our website for the public as well as for 
local and nationwide oncologists. 
 
MD Anderson Cancer Center serves as a resource through outreach programs such as MD Anderson 
Information Line, The Anderson Network, and the Information Service. Through these programs we will 
alert the community and health care professionals about this study. We also have periodic publications 
addressing various health related issues, including prevention of cancer. “CancerWise” for example is 
monthly publication with reports on advances in cancer prevention, treatment and research. Finally, local 
representatives of the American Cancer Society and the Susan G. Komen Breast Cancer Foundation, with 
which we have already close relationships, will help us advertising the study. The outreach programs will 
help us accruing minorities as well, such as MD Anderson Information Line, The Anderson Network, and 
CancerWise Community Speakers Bureau. In addition, to increase minority accrual and increase 
awareness about this study will be working together with some of the local organizations such as: Sisters' 
Network, Inc., One Hundred Black Women, National Association for the Advancement of colored People, 
Inc., Top Ladies of Distinction, Inc. African Methodist Episcopal Church. 
 
Retention Plan 
In our study, participants will return to clinic in 1 and 3 months; month 3 is usually the follow-up interval 
for our adjuvant patients during their initial 2 years after completing adjuvant therapy. Patients beyond 
these 2 years usually are seen every 6 months, therefore, for these patients there may be 2 extra visits 
(month 1 and 3) which would be sponsored by the study. 
 
We will also strive to retain participants by offering well-trained, friendly staff, consistent monitoring of 
Proprietary Information of MD Anderson

11 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
recruitment and adherence; and specific efforts early in the study to enthusiastically engage compliant 
participants in the trial. 
 
5. AGENT ADMINISTRATION 
 
Intervention will be administered on an outpatient basis.  Reported adverse events and potential risks are 
described in section 6.2. 
 
5.1 Dose Regimen and Dose Groups 
 
Participants will receive dasatinib at 40mg, or 80mg once a day or no drug. Dasatinib will be taken for 3 
months (+/- 7 days). If a dose is missed by more than 12 hours, the dose should be omitted. Tablets 
should not be crushed and be swallowed as a whole. Dasatinib can be taken with or without a meal. 
 
5.2 Study Agent Administration 
 
• 
The participant will self-administer dasatinib by mouth. 
 
5.3 Run-in Procedures 
N/A 
 
 
5.4 Prohibited Therapies 
Drugs that are considered category D (Consider therapy modification) and X (Avoid combination) using 
the Lexicomp database are prohibited. Concomitant drugs that fall into categories A (No known 
interaction), B (no action needed) and C (monitor therapy) are allowed. 
 
5.5 Restricted Therapies 
Drugs that are considered category D (Consider therapy modification) and X (Avoid combination) using 
the Lexicomp database are prohibited. Concomitant drugs that fall into categories A (No known 
interaction), B (no action needed) and C (monitor therapy) are allowed. 
 
 
5.6 Concomitant Medications 
 
• 
No other investigational therapy will be given to patients. 
 
• 
The use of anticancer agents (other than hormonal therapy) or radiation therapy is not allowed 
(an exception would be the use of megestrol acetate for the treatment of anorexia). 
 
• 
Patients enrolled in the Phase I portion of the trial may not receive GCSF or GMCSF during 
cycle 1 of therapy. The use of hematologic growth factors for the treatment of anemia is allowed 
at any time during protocol therapy. Patients enrolled in the Phase II portion of the trial or those 
who have completed >1 cycle of therapy in the phase I portion of the trial may receive growth 
factor support as per ASCO guidelines. 
 
• 
Drugs that are considered category D (Consider therapy modification) and X (Avoid 
combination) using the Lexicomp database are prohibited. Concomitant drugs that fall into 
categories A (No known interaction), B (no action needed) and C (monitor therapy) are allowed. 
 
5.7 Dose Modification 
 
For grade 1 toxicity or less, no dose modifications will be made. For grade 2 or greater toxicity probably, 
possibly, or definitely related to dasatinib, dasatinib will be held until recovery at least to grade 1 and 
patient will re-start at one lower dose level if applicable (80 mg to 40). For grade 3 or 4 toxicity the study 
Proprietary Information of MD Anderson

12 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
drug will be discontinued. 
 
5.8 Adherence/Compliance 
 
• 
Participants who are randomized to the treatment group will be evaluable if they received 
at least 75% of their assigned dasatinib dose.  No imputation will be performed on 
missing data 
 
• 
The following 2 methods will be used to monitor each participant’s agent compliance: 
1) Participants will be given a pill diary and instructed to initial it each time a 
dose is taken 
2) At the end of the treatment period, the actual quantity of unused drug will 
be compared to the anticipated amount of unused drug and participant pill 
diary. 
 
6. PHARMACEUTICAL INFORMATION 
 
6.1 Study Agent 
 
Dasatinib tablets are white to off-white, biconvex, film-coated tablets containing dasatinib, with the 
following inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, 
hydroxypropyl cellulose, and magnesium stearate. The tablet coating consists of hypromellose, titanium 
dioxide, and polyethylene glycol. 
 
Preclinical Toxicology 
 
Single or repeated oral administration of dasatinib principally affected the gastro-intestinal (GI) tract, 
including the liver, the hematopoietic, and lymphoid systems in rats and monkeys. Other prominent 
effects after single oral administration of dasatinib included renal and cardiac toxicity in rats at lethal 
doses, and cutaneous hemorrhage in monkeys. Dasatinib can also affect the immune system and bone 
turnover. 
 
Dasatinib in vitro activity in the HERG/IKr and Purkinje-fiber assays indicated a moderate liability for 
prolongation of cardiac ventricular repolarization (QT interval) in the clinic. However, there were no 
dasatinib -related changes observed in electrocardiograms, nervous system function, respirations and 
heart rate, blood pressure, or arterial oxygen saturation in single-dose, 10-day, or 1-month oral toxicity 
studies in monkeys. 
 
Dasatinib was found to exhibit a profile of broad-spectrum platelet inhibition best typified by anti-platelet 
agents such as the GPIIb/IIIa antagonists, integrelin and abciximab. 
 
Finally, modulation of SRC kinase activity could also affect osteoclast morphology and function and bone 
remodeling. This effect could potentially result in an increase in bone mineral density and a phenotype 
analogous to osteopetrosis(15). 
 
Clinical Pharmacokinetics 
 
The pharmacokinetics of dasatinib have been evaluated in 229 healthy subjects and in 137 patients with 
leukemia. 
 
Absorption 
 
Maximum plasma concentrations (Cmax) of dasatinib are observed between 0.5 and 6 hours (Tmax) 
following oral administration. dasatinib exhibits dose proportional increases in AUC and linear 
elimination characteristics over the dose range of 15 mg to 240 mg/day. The overall mean terminal half- 
life of dasatinib is 3–5 hours(14). 
 
Data from a study of 54 healthy subjects administered a single, 100-mg dose of Dasatinib 30 minutes 
Proprietary Information of MD Anderson

13 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
following consumption of a high-fat meal resulted in a 14% increase in the mean AUC of dasatinib. The 
observed food effects were not clinically relevant. 
 
Distribution 
 
In patients, dasatinib has an apparent volume of distribution of 2505 L, suggesting that the drug is 
extensively distributed in the extravascular space. Binding of dasatinib and its active metabolite to human 
plasma proteins in vitro was approximately 96% and 93%, respectively, with no concentration 
dependence over the range of 100–500 ng/mL(14). 
 
Metabolism 
 
Dasatinib is extensively metabolized in humans, primarily by the cytochrome P450 enzyme 3A4 (see 
section 7.6). CYP3A4 was the primary enzyme responsible for the formation of the active metabolite. 
Flavin-containing monooxygenase 3 (FMO-3) and uridine diphosphate-glucuronosyltransferase (UGT) 
enzymes are  also involved  in the formation  of  dasatinib  metabolites. In human liver microsomes, 
dasatinib was a weak time-dependent inhibitor of CYP3A4. 
 
The exposure of the active metabolite, which is equipotent to dasatinib, represents approximately 5% of 
the dasatinib AUC. This indicates that the active metabolite of dasatinib is unlikely to play a major role 
in the observed pharmacology of the drug.  dasatinib also had several other inactive oxidative metabolites. 
 
Elimination 
Elimination is primarily via the feces. Following a single oral dose of [14C]-labeled dasatinib, 
approximately 4% and 85% of the administered radioactivity was recovered in the urine and feces, 
respectively, within 10 days. Unchanged dasatinib accounted for 0.1% and 19% of the administered dose in 
urine and feces, respectively, with the remainder of the dose being metabolites(14). 
 
 
6.2 Rationale for Dose Selection: 
 
Since our aim in this pilot biomarker prevention study is to identify the minimal dose required to 
induce biomarker modulation by dasatinib in high risk breast epithelium and not to identify the 
maximum tolerated dose for antitumor efficacy, we will not perform a traditional phase I dose 
escalation study that is utilized in metastatic phase I studies (as MTD for anticancer treatment has 
already been defined). Previous studies have shown considerable toxicity with 100 mg of dasatinib, 
therefore, in our pilot biomarker modulation study, we will randomly assign patients to 0,40, or 80 mg 
daily dasatinib and perform ongoing evaluation of toxicity (please see toxicity evaluation section (12). 
 
6.3 Availability 
 
Dasatinib will be requested from BMS. As an alternative plan, dasatinib will be purchased using other 
funding mechanisms. 
 
6.4 Agent Accountability 
 
The PI, or a responsible party designated by the investigator, will maintain a careful record of receipt, 
disposition, and return of all study drugs on the Investigational Agent Accountability Record. All study 
drug supplies will be kept in a locked, limited access area. The study drug will not be used outside the 
context of the protocol. Under no circumstances will the investigator or other site personnel supply study 
drug to other patients, or clinics, or allow supplies to be used other than directed by this protocol. Study 
agent will not be transferred from one patient to another, or from one protocol to another. All other 
transfers (i.e. patient or PI moves) must be approved in advance by the study PIs. 
 
The investigator will maintain records documenting the receipt, use, loss or other disposition of the 
investigational product, including batch or code numbers, and account for it’s disposition on a subject-by- 
subject basis, including specific dates and quantities. The source document, documenting the subject’s 
Proprietary Information of MD Anderson

14 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
participation in this randomized clinical trial, must be documented in the medical and research records. 
Destruction will be documented in accordance with institutional SOPs. 
 
6.5 Packaging and Labels 
 
Dasatinib will be packaged in bottles as follows: 
• 
Dasatinib 20 mg film-coated tablets, 30 tabs/bottle 
Each bottle will be labeled in an open label.  Labels will contain, at a minimum, the following 
information: product name, tablet strength, batch number, directions for use, storage conditions, and 
appropriate caution statements. 
 
Storage-Handling and Disposal Dasatinib tablets should be stored in a secure area at 25⁰C 
(77⁰F); excursions permitted between 15–30⁰C (59–86⁰F). 
 
Procedures for proper handling and disposal of anticancer drugs should be considered. There is no general 
agreement that all of the procedures recommended in the guidelines are necessary or appropriate. 
 
Dasatinib tablets consist of a core tablet (containing the active drug substance), surrounded by a film 
coating to prevent exposure of pharmacy and clinical personnel to the active drug substance. However, if 
tablets are crushed or broken, pharmacy and clinical personnel should wear disposable chemotherapy 
gloves. Personnel who are pregnant should avoid exposure to crushed and/or broken tablets 
 
6.7 Registration 
 
Participating institutions will register all participants per their IRB institutional policy.  In addition, 
participants will be registered and randomized at MDACC.  Registration will be completed in the 
MDACC Office of Research Administration computer system CORe (Clinical Oncology 
Research).  CORe will assign the overall protocol accession number.   The randomization program 
based on this method will developed by the Department of Biostatistics, and the program will be 
available via an intranet web site of MDACC. 
 
6.8 Agent Administration 
 
Upon randomization one month supply of study drug will be dispensed to the patients randomized to the 
treatment arms. Additional bottles will be dispensed at 1 month clinic visits, as necessary, to ensure that 
the subject has sufficient study drug to last until the next planned clinic visit. Follow-up schedule will be 
taken into consideration when drug is dispensed and those with the modified visit schedule will be 
provided an adequate supply to last until next visit. 
 
During study participation, subjects will be asked to: self-administer the study medication; avoid certain 
medications/supplements and complete daily logs to record study agent intake, concomitant 
medications, and AEs. Subjects are expected to: maintain ≥75% compliance with study agent intake; 
comply with dietary, medication and supplement restrictions; and complete the daily log. 
 
6.9 Destruction of Dasatinib 
 
At the completion of investigation, all unused study agent will be destroyed according to 
institutional guidelines. 
 
7. CLINICAL EVALUATIONS AND PROCEDURES 
 
7.1 Schedule of Events 
Please refer to Table 1 that lists baseline testing/pre-study evaluation, agent administration, study 
assessments, procedures and case report forms. 
Proprietary Information of MD Anderson

15 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
 
7.2 Baseline Testing/Pre-study Evaluation 
 
7.2.1 
If individual is eligible as outlined in section 4.1, she will sign consent and she will 
be assigned a participant identification number at the time of enrollment and the 
following procedures will be undertaken: 
 
7.2.2 
Data collection will include: medical history, demographic information including 
race, age, height, weight, cancer family history, reproductive history (age at 
menarche, age at first pregnancy, outcome of each pregnancy, lactation and duration 
of each episode of lactation, history of previous benign breast disease (age at each 
breast biopsy and histologies identified in each breast biopsy), hormonal medication 
use (age at first use and duration of use of oral contraceptives, hormone replacement 
or fertility drugs),and usual weekly alcohol consumption. 
 
7.2.3 
General physical exam, including a clinical breast examination, if these exams were 
not performed in the last 12 months.  If the physical exam and a clinical breast exam 
were performed within the past12 months, do not need to repeat them for baseline.  If 
a breast mass is found on initial physical exam, the participant will receive an 
appropriate evaluation, and will not participate in the study until the mass has been 
definitively classified as benign. 
 
7.2.4 
Gynecology evaluation within the last 5 years (as suggested by patient’s gynecologist).  
Participants with a prior hysterectomy alone, hysterectomy and bilateral salpingo-
oophorectomy, or bilateral salpingo-oophorectomy alone are exempt from this 
requirement. 
 
7.2.5 
Bilateral or unilateral mammogram within 12 months prior to registration. 
 
7.2.6 
Blood draw for CBC with differential, platelet count, electrolyte, Magnesium, liver 
panel (LFT) within 3 months prior to randomization, EKG (within 1 month),  if 
normal (upper limit normal is sufficient for liver panel, creatinine), and if eligible, 
patient will proceed to 7.2.8 
 
7.2.7.  
Urine pregnancy test (if not already completed within 14 days prior to randomization 
or start of study agent, order STAT for results to be available prior to drug 
administration) for women of childbearing potential. 
 
7.2.8 
Breast periareolar fine needle aspiration (FNA),(baseline) 
(If participant is on aspirin (except those who take 81 mg aspirin), non-steroidal anti-
inflammatory drugs and Vitamin E, she will be instructed to discontinue these and 
return in 7-10 days for the FNA) FNA procedure is described in section 7.5.6. 
 
7.2.9 
Blood draw for research biomarkers (Day 0) 
 
7.2.10 
The participant will be randomized to drug or no drug and the ones that are 
randomized to dasatinib will be provided with a drug kit with a 3 month supply, and a 
pill diary and will be instructed to return any unused drugs. The participant will start 
dasatinib within 7 days. Concomitant medications will be documented. 
 
7.2.11 
A 3-month follow-up (+/- 7 days) will be scheduled and participants will be instructed 
to call if any symptoms occur. 
 
7.3 Evaluations During Study Intervention 
Proprietary Information of MD Anderson

16 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
 
At month 1 and 2: Study nurse will call the participant to document and grade the presence of adverse 
events, compliance and concomitant medications. 
 
 
7.4 Evaluations at Completion of Study Intervention 
 
Month 3 clinic visit will include: Vital signs, AE, concomitant medication, and review of study 
medication taken and pill counts. Participants will return agent diary and unused study medication. 
Blood sampling for repeat biomarkers studies, and breast FNA will be performed (The study drug can be 
taken on the biopsy day). 
 
7.5 Methods for Clinical Procedures 
 
7.5.1 Medical history: Research staff will obtain data from a prospectively maintained research 
database that all UT MDACC breast cancer patients are entered in. 
 
7.5.2 Karnofsky performance status: The Karnofsky Performance Scale Index allows subjects to 
be monitored for basic functional status and to monitor any functional impairment. Although no 
changes in functional impairment are anticipated, we plan to utilize this scale to ensure optimum 
functional status to participate in this clinical trial. This will be recorded in the participant’s CRF. 
 
7.5.3 Study agent intake log (pill diary): Participants will be provided with a Study Agent Intake log 
(pill diary) which they will be required to complete daily. The pill diary will require the subject to 
check that study agent has been taken. Monthly, subjects will be contacted by a member of the research 
staff by phone for review of: i) pill diary, and; ii) use of concomitant medications; iii) Anticipated and 
unanticipated, grades of constitutional, dermatological, gastrointestinal (GI), metabolic and pain 
symptoms noted; 
 
7.5.4 Adverse Events (AEs): Adverse Events (AEs): All AEs that are reported by the subject, 
detected during a visit, physical examination, or laboratory work-up will be recorded in the 
participant’s study record and recorded on the CRF. All AEs that occur after the informed consent is 
signed will be recorded on the AE CRF whether or not related to study agent. The following 
information will be captured for each AE: date reported; verbatim term; Common Toxicity Criteria 
(CTCAE Term v 4.0); onset and resolution date; severity grade; attribution to study agent; whether or 
not the event was reported as an SAE; action taken; whether or not the subject dropped due to the 
AE; outcome; and comments; 
 
7.5.5 Fine Needle Aspiration: In order to evaluate changes in biomarkers patients will undergo 
FNA at baseline and 3 month after taking dasatinib. The procedure is as follows: 
 
The skin of the periareolar region (upper and lower outer quadrants) is cleansed with an alcohol prep 
pad infiltrated with 0.1m. of 1% Lidocaine mixed 9:1 within 8.3 sodium bicarbonate. We will obtain 
pre and post dasatinib treatment FNA from breast tissue (only 1 breast; the same breast will be used 
for the repeat FNA) from the most dense area, mostly at 3 o’clock position and 9 o’clock position, 4 
passes at each position, 8 passes total.  A 25-gauge needle attached to a 10 ml syringe in a syringe 
holder is used to perform the aspiration. The needle is inserted into the breast to a distance of 1 – 1 
½. Suction is applied by pulling on the plunger of the syringe, and the needle is moved back and 
forth rapidly in the same plane within the most dense breast tissue. Suction is maintained until some 
material appears in the clear plastic needle hub (this may require as many as 20 up and down 
motions of the needle with continuous suction). When material appears in the hub of the needle, the 
syringe plunger is released and the needle is withdrawn. The material obtained by fine needle 
aspiration is rinsed into the CytoLyt fixative solution (methanol based). The procedure is repeated, 
using a disposable needle and a syringe. Once cells are in CytoLyt, the cells will be fixed and the 
Proprietary Information of MD Anderson

17 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
vial can be left in room temperature until next step. The cells are spun down and an aliquot of the 
sediment is re-suspend in PreserveCyt solution and then thin-layered slides are prepared using the 
ThinPrep Processor.  Thin-layer slide is fixed with 95% alcohol and stained with Papanicolaou and 
cellularity of this slide is evaluated.  We then re-suspend the cells in the remaining sediment in 
PreserveCyt solution and prepare as thin-layer slides, fix them with 95% alcohol and air-dry and 
store them at -80C for the proposed markers.  A preprinted label will be attached to identify all 
sample vials. Manual pressure is held over the biopsy site between each needle pass and for 10 
minutes after the last pass; participants will then be given ice packs to put pressure over the biopsy 
site for 20 minutes. 
 
7.5.6 Biomarkers to be assessed: 
 
Cytomorphology: FNA Cytomorphology is a valid and modifiable risk biomarker and response 
indicator for early prevention trials and has been reported to be present about 25% (range 15-50%) 
of high risk individuals{Arun, #3399}, {Fabian, 1998 #3400}.Cytomorphology and Ki-67 
expression are independent variables considered complementary (17).Cytomorphology will be 
assessed by a single expert breast cytopathologist who will assign a categorical assessment of 
nonproliferative, hyperplasia, borderline hyperplasia with atypia, or hyperplasia with atypia (18). 
The pathologist will be blinded as to the pre and post dasatinib samples. 
 
Cell proliferation by Ki-67: The expression of the human Ki-67 protein is associated with cell 
proliferation, as this protein is present during all active phases of the cell cycle (G1, S, G2 and 
mitosis), but is absent from resting cells G0, making it an excellent marker for determining the 
growth fraction of a given cell population (19). Ki-67 has shown rapid modulation in previous 
studies, including 14-day treatment with Tamoxifen. It has also demonstrated correlation with 
subsequent clinical response (20). Recent studies (14), (21), have demonstrated that Ki-67 
proliferation index is an established, valid,  reliable marker of proliferation and that changes in Ki-67 
in FNA is a valid IEB of chemoprevention efficacy. Slides in which more than 500 epithelial cells are 
visible by Papanicolaou staining will be further processed for Ki-67. After de-staining, antigen 
retrieval will be performed with a 10 nM/l citrate buffer (pH 6) in a Biocare (Walnut Creek, CA, 
USA) decloaking chamber (DC 2002) for 2 min at 120°C. Slides will be stained with a MIB-1 
monoclonal antibody (M7240 Dako Cytomation; Dako, Carpenteria, CA, USA) at a 1:20 dilution 
using a Dako autostainer. Hyperplastic clusters will be preferentially assessed, and the number of 
cells with unequivocal nuclear staining out of a total of 500 cells will be assessed. 
 
Apoptosis by the Caspase-3 Method: From Cell Signaling Technology (CST) we will obtain the 
Apoptosis Marker: Signal Stain Cleaved Caspase-3 (Asp 175) IHC Detection Kit. This is a “ready to 
use” system designed to detect the activation of caspase-3 in human cell preps by 
immunohistochemistry with which we have extensive experience. 
 
Other markers: If samples permit slides that are prepared using the Thin Prep technique from 
Cytyc will be used for immunohostochemitry studies using previously described antibodies for 
EGFR, phosphorylated EGFR and bcl-2, p-Y418-Src, p-Y-118-Paxillin, and markers identified in 
Aims 1 and 3 of the grant (IGF-1, IGFBP1 and 3). 
 
Proteomic Profiling: Markers of proliferation and apoptosis as well markers involved in ER 
negative breast cancer development pathway, including the src and mTOR pathway will be 
evaluated using the reverse phase protein microarray (RPPM) method:  Epithelial cell clusters 
prepared from breast FNAs are microdissected using an AutoPix Automated Laser Capture 
Microscope. To ensure that we distinguish 1) epithelial cells versus stromal cells, and 2) identify the 
degree of cytological atypia, slides will be photographed before microdissection. As in preliminary 
data, 100 total and phosphoproteins will be profiled. Total protein concentrations will be assessed by 
Spyro Ruby fluorescent staining (22), (23). RPPM will be performed using MicroVigeneTM image 
Proprietary Information of MD Anderson

18 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
analysis software (24). Arrays will be scanned, spot intensity normalized, and standard single value 
will be generated for each sample (Image Quant v5.2). Spot intensity will be integrated and 
background intensity calculated (JMP v5.0, SAS). Key technological components of RPPM offer 
unique advantages over tissue or antibody arrays(22), (23).  RPPM uses denatured lysate so antigen 
retrieval, which is a limitation for tissue arrays, is not a problem. Secondly, each sample is printed 
on the array in serial dilution, providing an internal standard. Finally, RPPM does not require direct 
labeling of the sample, thus improving reproducibility, sensitivity, and robustness. 
 
Serum IGF pathway markers: IGF-1 and IGFBP3 are potential intermediate biomarkers for short 
term breast cancer prevention trials (25), (26), {Arun, 2011 #3436}. 
 
Non-fasting blood sample of approximately 10 ml will be drawn at the baseline visit and at 3 months, 
using sterile needles into a 10 ml speckled red top SST tube. The blood in speckled red top tubes will 
be processed at the clinic site by standing for 20-60 min to clot, then spinning for 20 minutes at 3200 
rpm. Serum will be aliquotted into 3 tubes (1-2.0 ml each), and placed in a -70º C freezer.
Proprietary Information of MD Anderson

19 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
Table 1. SCHEDULE OF EVENTS 
 
Evaluation/Procedure 
Registration 
Baseline 
Month 1h 
Month 2h 
Month 3 / 
Early 
Terminationh 
Informed Consent 
Xg 
 
 
 
 
Assess Eligibility 
X 
X 
 
 
 
Medical History 
 
X 
 
 
 
Physical Exam 
 
Xf 
 
 
 
Vital Signs 
 
X 
 
 
 
Height and Weight 
 
X 
 
 
 
Laboratory Tests  
 
Xa 
 
 
 
EKG 
 
X 
 
 
 
Mammogram 
 
Xb 
 
 
 
Gynecologic 
Evaluation 
 
Xe 
 
 
 
Pregnancy test 
 
Xc 
 
 
 
Breast FNA 
 
X 
 
 
X 
Blood Biomarkers 
 
X 
 
 
X 
Concomitant 
Medications 
 
X 
Xd 
Xd 
X 
Dispense Study 
Agent 
 
X 
 
 
 
Collect Study Agent 
 
 
 
 
X 
Review Diary 
 
X 
Xd 
Xd 
X 
Adverse Events 
 
 
Xd 
Xd 
X 
Nurse telephone 
follow-up 
 
 
Xd 
Xd 
 
 
a = Normal CBC, platelet count, electrolyte, Magnesium, liver panel, creatinine within last 3 months and 
EKG within one month prior to randomization 
b = Normal mammogram within last 12 months prior to randomization 
c = Negative pregnancy test within 14 days prior to randomization or start of the study agent, if 
applicable.  
d = During nurse phone call 
e = Gynecology evaluation within the last 5 years prior to randomization. Participants with a prior history 
of hysterectomy alone, hysterectomy and bilateral salpingo-ooporectomy, or bilateral salpingo-
ooporectomy alone are exempt from this requirement. 
f = Normal physical exam within last 12 months prior to randomization 
g = Informed consent is valid within 30 days only prior to the study drug; otherwise, a new 
informed consent should be obtained before reassessing the subject for protocol eligibility 
h = A window of +/- 7days is allowed for these visits 
 
 
Proprietary Information of MD Anderson

20 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
8. CRITERIA FOR EVALUATION AND ENDPOINT DEFINITION 
 
Study endpoints in our study consist of biomarker changes in breast tissue and serum. Samples for the 
evaluation of these markers will be obtained pre study initiation and at 3 months (+/- 7 days). The specifics 
are described below. 
 
8.1 
Primary Endpoint 
 
The primary goal is to evaluate Dasatinib induced reduction of proliferation. Ki-67 will be measured in 
baseline and month 3 contralateral breast FNA samples. 
 
8.2 Secondary Endpoints 
 
8.2.1 Cytology: Changes in cytology in baseline and month 3 FNA samples will be evaluated.  The 
cytology criteria used for the interpretation of the smear are similar to the 1997 consensus criteria 
published by the National Cancer Institute: Inadequate cellular material for diagnosis, normal 
epithelial cells, atypical hyperplasia, suspicious and malignant. 
 
8.2.2 Proliferation and apoptosis analysis of FNA samples: EGFR, P-EGFR, bcl-2, CC3 expression 
in FNA samples at baseline and at month 3 (+/- 7 days) will be evaluated by immunohistochemistry 
(IHC). Scoring will be performed by Dr. Yun Gong. 
 
8.2.3 Proteomic profile analysis of FNA samples: Src, AMPK and M-TOR related pathways will be 
evaluated in FNA samples obtained at baseline and at 3 months after dasatinib treatment. Samples will 
be evaluated by Dr. Seewaldt. 
 
8.2.4 Serum markers: IGF pathway (IGF-I, IGFBP-1, IGFBP-3) at baseline and at 3 months will 
be evaluated in Dr. Arun’s laboratory. 
 
8.3 
Off Agent Criteria 
 
Participants may stop taking study agent for the following reasons: completed the protocol-prescribed 
intervention, adverse event or serious adverse event, inadequate agent supply, noncompliance, 
concomitant medications, or medical contraindication. Participants will continue to be followed, if 
possible, for safety reasons and in order to collect endpoint data according to the schedule of events. In 
case participants will be off agent but have taken at least 1 dose of dasatinib and undergo a month 3 FNA, 
they will be statistically evaluable for biomarker endpoint. 
 
8.4 Off Study Criteria 
 
Participants may go ‘off-study’ for the following reasons: the protocol intervention and any protocol- 
required follow-up period is completed, adverse event/serious adverse event, lost to follow-up, non- 
compliance, concomitant medication, medical contraindication, recurrent disease, withdraw consent, or 
death. 
 
9. 
SPECIMEN MANAGEMENT 
 
9.1 Laboratories 
 
9.1.1 Obtaining and processing of breast FNA samples and cytopathologic interpretation will be 
performed, evaluated and stored at the MD Anderson Cancer Center Cytopathology laboratory 
(Address: UT M.D. Anderson Cancer Center Department of Cytopathology Unit 53, 1515 
Holcombe Blvd, Room G3.3628, Houston, Texas 77030-3721) FNA samples in CytoLyt 
Proprietary Information of MD Anderson

21 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
labeled with the study ID from DUKE will be sent to the MD Anderson Cancer Center 
Cytopathology laboratory (same address), for centralized cytology review by Dr. Yun Gong 
 
9.1.2 
KI-67, EGFR, P-EGFR, bcl-2, CC3 p-Y418-Src, p-Y-118-Paxillin expression in FNA samples 
will be performed by IHC analysis at MD Anderson Cancer Center, Pathology 
Immunohistochemistry Core Laboratory for centralized staining. Scoring will be performed by 
Dr. Yun Gong. 
 
9.1.3 
Proteomic profile analysis involving the src, AMPK and mTOR pathway in FNA samples that 
are labeled as in section 7.5.5 will be performed by Dr.Victoria Seewaldt at Duke University 
(Shipping address: Duke university Medical Center, 2301 Erwin Rd, Rm 221A MSRB, 
Durham, NC 27710) 
 
9.1.4 
IGF pathway (IGF-I, IGFBP-1, IGFBP-2), leptin, adiponektin at baseline and at 3 months will 
be evaluated in Dr.Arun’s laboratory (1515 Pressler Street, Unit 1354, Houston, TX 77030). 
 
9.1.5 
Routine laboratory tests for eligibility at baseline (Section 7.2) will be performed at each 
Institution’s standard laboratory. 
 
9.2 Collection and Handling Procedures 
 
Fine Needle Aspiration (FNA): 
 
We will obtain pre and post dasatinib treatment FNA from breast tissue at baseline and at 3 months (+/- 7 
days) from each participant as described in section 7.6. An average of 6-8 separate needle passes will be 
performed in 1 breast. The material obtained by fine needle aspiration is rinsed into the CytoLyt fixative 
solution. The procedure is repeated, using a disposable needle and a syringe. Once cells are in CytoLyt, the 
cells will be fixed and the vial can be left in room temperature until next step.   Cells in the CytoLyt are 
spinned down and an aliquot of the sediment is re-suspend in PreserveCyt solution and then thin-layered 
slides are prepared using the ThinPrep Processor.  Thin-layer slide is fixed with 95% alcohol and stained 
with Papanicolaou and cellularity of this slide is evaluated.  The cells in the remaining sediment will be re-
suspended in PreserveCyt solution and thin-layered slides will be prepared. Slides will be fixed with 95% 
alcohol and air-dried and stored at -80⁰C for the analysis of proposed markers.  One FNA pass will be 
placed in saline solution and frozen at -80⁰C.  A preprinted label will be attached to identify all sample 
vials. 
 
Blood Collection: 
 
Peripheral blood will be obtained by venipuncture at baseline and at 3 months (+/- 7 days). Twenty ml blood 
will be collected in 2 red top tubes for biomarkers analysis (baseline and at 3 months (+/- 7 days)) and be 
processed within 24hrs of collection. If blood is not processed within 24hrs, a new sample will need to be 
collected and processed correctly.  
 
For the purpose of tracking samples: A pre-printed label will be attached to identify all sample vials. 
Blood will be stored at -20⁰C, serum will be stored at -80⁰C. 
 
9.3 
Tissue Banking 
 
If the participants agree, unused FNA samples without participant identifiers (except study PID) will be 
placed into 1.5 ml RNA later (Ambion). This will be held at room temperature for 15 minutes then snap 
frozen and stored at - 80⁰C in our (MDACC) Institutional Tissue Bank Core Facility/Cytopathology Lab. 
 
Unused serum will be stored at -80⁰C in Dr. Arun’s Laboratory. 
 
Proprietary Information of MD Anderson

22 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
10. REPORTING ADVERSE EVENTS 
 
DEFINITION: An adverse event (AE) is any untoward medical occurrence in a study participant.  An AE 
does not necessarily have a causal relationship with the treatment or study participant.  An AE can 
therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or 
disease temporally associated with participation in a study, whether or not related to that participation. This 
includes all deaths that occur while a participant is on a study. 
 
A list of adverse events that have occurred or might occur (Reported Adverse Events and Potential Risks) 
can be found in Section 6.2, Pharmaceutical Information as well as the Investigator Brochure or package 
insert. 
 
10.1 Adverse Events 
 
10.1.1 Reportable Adverse Events 
 
All adverse events that occur after the informed consent is signed (including run-in) must be 
recorded on the adverse event CRF (paper and/or electronic) whether or not related to study agent. 
 
10.1.2 AE Data Elements: 
• 
AE reported date 
• 
AE Verbatim Term 
• 
CTCAE Category (v4.0) 
• 
CTCAE Term (v 4.0) 
• 
Event onset date and event ended date 
• 
Severity grade 
• 
Attribution to study agent (relatedness) 
• 
Whether or not the event was reported as a Serious Adverse Event (SAE) 
• 
Whether or not the participant dropped due to the adverse event 
• 
Action taken with the study agent 
• 
Outcome of the event 
• 
Comments 
 
10.1.3 Severity of AEs 
 
10.1.3.1 Adverse event will be identified using the NCI Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.0.  The CTCAE provides descriptive terminology and a 
grading scale for each adverse event listed.  A copy of the CTCAE can be found at 
http://ctep.cancer.gov. 
 
AEs will be assessed according to the CTCAE grade associated with the AE term.  AEs 
that do not have a corresponding CTCAE term will be assessed according to their impact 
on the participant’s ability to perform daily activities as follows: 
 
 
Grade Severity 
Description 
1 
Mild 
• 
Barely noticeable, does not influence functioning 
• 
Causing no limitations of usual activities 
2 
Moderate 
• 
Makes participant uncomfortable, influences functioning 
• 
Causing some limitations of usual activities 
3 
Severe 
• 
Severe discomfort, treatment needed 
• 
Severe and undesirable, causing inability to carry out 
usual activities 
Proprietary Information of MD Anderson

23 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
4 
Life threatening 
• 
Immediate risk of death 
• 
Life threatening or disabling 
5 
Fatal 
• 
Causes death of the participant 
 
10.1.4 Assessment of relationship of AE to treatment 
 
The possibility that the adverse event is related to study drug will be classified as 
one of the following:  unrelated, unlikely, possible, probable, definite. 
 
10.1.5 Follow-up of AEs 
 
All AEs, including lab abnormalities that in the opinion of the investigator are 
clinically significant, will be followed according to good medical practices and 
documented as such. 
 
10.2 
Serious Adverse Events 
 
10.2.1 DEFINITION: ICH Guideline E2A and Fed. Reg. 62, Oct. 7, 1997 define serious 
adverse events as those events, occurring at any dose, which meet any of the 
following criteria: 
• 
Results in death 
• 
Is life threatening (Note: the term life-threatening refers to an event in 
which the patient was at risk of death at the time of the event; it does not 
refer to an event 
which hypothetically might have caused death if it were more severe). 
• 
Requires inpatient hospitalization or prolongation of existing hospitalization 
• 
Results in persistent or significant disability/incapacity 
• 
Is a congenital abnormality/birth defect 
• 
Events that may not meet these criteria, but which the investigator finds very 
unusual and/or potentially serious, will also be reported in the same manner 
 
 
 
10.2.2 Participating organization will comply with applicable regulatory requirements 
related to reporting SAEs to their IRB. 
 
 
11. 
STUDY MONITORING 
 
Please refer to Appendix A. 
 
 
12. 
STATISTICAL CONSIDERATIONS 
 
12.1 Study Design/Endpoints 
 
This is a phase I biomarker modulation study of dasatinib in breast tissue of women who are at 
increased risk. To have a total of 60 participants, we have built in a 10% attrition rate and will accrue 66 
participants. Participants will be randomized into two treatment groups and one no treatment control group 
(N=15). The two treatment groups are 40 mg qd (N=30), and 80 mg qd (N=15) of dasatinib. The primary 
endpoint will be the change in Ki-67 before and after 3 months of dasatinib treatment in breast tissue of 
high-risk women. Ki-67 is measured as a continuous variable and a one-way ANOVA followed by 
Dunnett’s multiple comparison test comparing the change of Ki-67 of each of the three treated groups 
with control. The purpose of this study is to determine the minimum biological effective dose, which is 
Proprietary Information of MD Anderson

24 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
defined as the lowest dose where the change of Ki-67 is significantly different from that in the control group. 
Based on the recent report by Fabian et al. (26), the baseline Ki-67 value (in % of cell positive) is about 
6.5% with a range between 0% and 40%. 
 
12.2 Sample Size/Accrual Rate 
 
The primary endpoint is the change of Ki-67 between pre-treatment and post treatment. Relative difference 
of the Ki-67 change between groups is used to evaluate the treatment effect. We assume that the change 
of Ki-67 after the treatment is positively associated with the dose level. Monte Carlo simulations have been 
performed to analyze the power for the multiple comparisons using the Dunnett’s two-sided test procedure, 
where the sample mean in each treatment group is compared with the sample mean in the control group. 
A one-way design with the sample size of 15 and 30 in the two treatment groups and 15 in the control 
group can achieve an any-pair power of 0.87 assuming the effect size of 1 and the significance level of 
0.05. The any-pair power is defined as the probability of detecting the significant difference between any 
treatment groups and the control group. The effect size is the standardized mean difference between the 
treatment group and the control group, which is the ratio of detectable difference between the two groups 
and the common standard deviation within groups. Based on preliminary data (26), the standard deviation 
is about 10% for a single Ki-67 measure at the baseline or after treatment. Under a conservative assumption 
that the correlation coefficient between the before and after treatment Ki-67 is 0.5, the standard deviation 
of the Ki-67 modulation is also 10%. Therefore, an effect size of 1 corresponds to a Ki-67 change of 10% 
and an effect size of 1.2 corresponds to a Ki-67 change of 12%. With 30 and 15 participants in the two 
treatment groups, we will have at least 87% power to detect an effect size of 1.0 or larger. Power calculations 
were computed in PASS 2005. 
 
 
Effect Size 
Power to detect significance difference between any pairs 
0.8 
0.70 
1.0 
0.87 
1.2 
0.96 
 
In addition to the above analysis, if the data deviate from Gaussian distribution, proper transformation will 
be sought and nonparametric methods will be applied to provide valid data analysis. Analysis of 
covariance (ANCOVA) adjusted by baseline covariates associated with Ki-67 will be used to increase the 
statistical power for identifying biologically effective treatments 
 
12.3 Randomization and Stratification 
 
No stratification factors will be used in this relative small phase I study (compared to phase III). A random 
permutated block design with a block size of 4 or 8 will be used to ensure balance in randomization. 
 
12.4 Primary Endpoint 
 
The primary endpoint will be the change in Ki-67 before and after 3 months of dasatinib treatment. As 
indicated in Section 13.1, a one-way ANOVA by Dunnett’s multiple comparison test will be applied for 
analyzing the primary endpoint. 
 
12.5 Secondary Endpoints 
 
Secondary endpoints include evaluation of other proliferation and apoptosis markers (EGFR, CC3, bcl-2, 
ER, p21, p27), metabolites of the drug, and HMG-CoA reductase genotype. These will be exploratory 
endpoints performed and analyzed as samples permit. Descriptive statistics will be computed to estimate 
the distribution of the biomarkers and the change of biomarker values before and after treatment. 
Exploratory data analysis will be applied to check for outliers and to have a preliminary evaluation of the 
treatment effect by dose and association among various variables. Other standard statistical methods for 
Proprietary Information of MD Anderson

25 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
analyzing continuous and categorical data will be applied whenever appropriate. 
 
12.6 
Reporting and Exclusions 
 
All evaluable participants in the study will be evaluated for toxicity and efficacy. 
 
12.7 
Evaluation of Toxicity 
 
All participants will be evaluable for toxicity from the time of randomization. 
An event with an attribution of possible, probably, or definite is considered related. 
 
Bayesian toxicity monitoring schema will be used to monitor toxicity profile in the treatment arms. Each 
treatment arm will be monitored separately for toxicity.  “Severe Toxicity” is defined as grade 3 or 4 
toxicity related to the current dose level. The toxicity monitoring will start after enrolling at least 3 
participants in each dose level.  If a dose level is terminated due to the toxicity, the rest of the participants 
will be assigned to the lower dose levels only. 
We denote the probability of toxicity for each dose level as θi, i=1, 2 and assume that no toxicity is 
observed in the control group. The treatment will be stopped early if 
 
Pr[θi >0.10 | data ] > 0.85, i=1, 2 
 
for dose level i and higher dose levels.  In other words, the trial will be terminated if there is a greater than 
85% chance to observe more than 10% toxicity at 40mg level.  We assume that the prior distribution of θi 
follows a Beta (0.05, 0.95), which implies that the prior toxicity rate is 5% for each dose level. The choice 
of the parameters are based on prior data suggesting that about 5% of toxicity is expected in this drug and 
higher than 10% toxicity is considered unacceptable. 
 
The stopping boundary and the probability of early stopping are presented in Tables 1 and 2 below. 
 
The trial will be monitored for each dose level according to the following stopping boundaries for severe 
toxicity. 
 
Table 1. Toxicity Monitoring Boundaries 
 
Among number of 
Participants 
Recommend stopping dose levels if 
number of severe toxicity 
observed >= 
3-7 
2 
8-14 
3 
15-21 
4 
22-28 
5 
29-30 
6 
 
Table 2. Probability of early termination of a dose level due to severe toxicity 
 
True Severe 
toxicity rate 
Probability of early 
terminating 40mg level 
(therefore the trial) 
Probability of 
early terminating 
80mg level 
5% 
0.06 
0.06 
10% 
0.29 
0.22 
15% 
0.56 
0.42 
20% 
0.78 
0.63 
Proprietary Information of MD Anderson

26 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
 
12.8 
Evaluability 
 
Participants who are randomized to the treatment group will be evaluable if they received at least 75% of 
their assigned dasatinib dose.  No imputation will be performed on missing data. 
 
 
12.9 
Interim Analysis 
 
There will not be interim analysis on efficacy of the study. However, toxicity will be monitored closely. 
 
 
 
13. ETHICAL AND REGULATORY CONSIDERATIONS 
 
13.1 
Institutional Review Board Approval 
 
Prior to initiating the study the Protocol Lead Investigator at the Lead Organization must obtain written 
approval to conduct the study from the appropriate IRB. Should changes to the study become necessary, 
protocol amendments will be submitted to the IRB. 
 
 
13.2 
Informed Consent 
 
All potential study participants will be given a copy of the IRB-approved Informed Consent to review. The 
investigator will explain all aspects of the study in lay language and answer all questions regarding the 
study. If the participant decides to participate in the study, he/she will be asked to sign the Informed 
Consent document. The informed consent document is considered valid for 30 days from the participant’s 
signature date to begin treatment.  If treatment has not begun within 30 days following the signature date 
listed on the informed consent document then the participant must be reassessed for protocol eligibility 
and a new consent document completed. The study agent(s) will not be released to a participant who has 
not signed the Informed Consent document. Participants who refuse to participate or who withdraw from 
the study will be treated without prejudice. 
 
Participants must be provided the option to allow the use of blood samples, other body fluids, and 
tissues obtained during scheduled testing, operative procedures, or other standard medical practices for 
further research purposes. A separate signature area is required to allow participants to opt out of 
allowing tissue to be used for further research. 
 
13.3 Other 
 
This trial will be conducted in compliance with the protocol, Good Clinical Practice (GCP), and the 
applicable regulatory requirements. 
 
REFERENCES 
 
1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for 
prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J 
Natl Cancer Inst. 1998;90:1371-88. 
2. Gail M, Brinton L, Byar D, Corel D, Green S, Schairer C. Projecting individualized probabilities of developing 
breast cancer for white females who are being examined annually. J Nat Cancer Inst. 1989;81:1879-86. 
3. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast 
cancer. N Engl J Med. 1992;326:1756-61. 
4. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J 
Clin Oncol. 2000;18:3172-86. 
5. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 
1997;13:513-609. 
Proprietary Information of MD Anderson

27 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
6. Tan M, Li P, Sun M, Yin G, Yu D. Upregulation and activation of PKC alpha by ErbB2 through Src promotes 
breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. 
Oncogene. 2006;25:3286-95. 
7. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004;4:470-80. 
8. Wilson GR, Cramer A, Welman A, Knox F, Swindell R, Kawakatsu H, et al. Activated c-SRC in ductal 
carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer. 
2006;95:1410-4. 
9. Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon C, et al. Src promotes estrogen-dependent estrogen 
receptor alpha proteolysis in human breast cancer. J Clin Invest. 2007;117:2205-15. 
10. Hiscox S, Morgan L, Green T, Nicholson RI. Src as a therapeutic target in anti-hormone/anti-growth factor- 
resistant breast cancer. Endocr Relat Cancer. 2006;13 Suppl 1:S53-9. 
11. Fabian CJ, Kimler BF, Elledge RM, Grizzle WE, Beenken SW, Ward JH. Models for early 
chemoprevention trials in breast cancer. Hematol Oncol Clin North Am. 1998;12:993-1017. 
12. Dunn BK, Kramer BS, Ford LG. Phase III, large-scale chemoprevention trials. Approach to chemoprevention 
clinical trials and phase III clinical trial of tamoxifen as a chemopreventive for breast cancer--the US National 
Cancer Institute experience. Hematol Oncol Clin North Am. 1998;12:1019-36, vii. 
13. Arun B, Valero V, Cook E, Lammy J, Smith T, Hortobagyi G, et al. Phase II chemoprevention trial of 
celecoxib using ductal lavage. Breast Cancer Res and Treatment. 2003;71:126a. 
14. Arun B, Valero V, Logan C, Broglio K, Rivera E, Brewster A, et al. Comparison of ductal lavage and random 
periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin 
Cancer Res. 2007;13:4943-8. 
15. Rosen PP, Groshen S, Kinne DW, Hellman S. Contralateral breast carcinoma: an assessment of risk and 
prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up. Surgery. 1989;106:904-
10. 
16. Robinson E, Rennert G, Rennert HS, Neugut AI. Survival of first and second primary breast cancer. 
Cancer. 1993;71:172-6. 
17. Khan QJ, Kimler BF, O'Dea AP, Zalles CM, Sharma P, Fabian CJ. Mammographic density does not correlate 
with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle 
aspiration from women at high risk for breast cancer. Breast Cancer Res. 2007;9:R35. 
18. Zalles CM, Kimler BF, Simonsen M, Clark JL, Metheny T, Fabian CJ. Comparison of cytomorphology in 
specimens obtained by random periareolar fine needle aspiration and ductal lavage from women at high risk for 
development of breast cancer. Breast Cancer Res Treat. 2006;97:191-7. 
19. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 
2005;23:7212-20. 
20. Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, et al. Effect of Raloxifene on Breast 
Cancer Cell Ki67 and Apoptosis: A Double-Blind, Placebo-controlled, Randomized Clinical Trial in 
Postmenopausal Patients. Cancer Epidemiol Biomarkers Prev. 2001;10:961-6. 
21. Fabian CJ, Kimler BF, Zalles CM, Khan QJ, Mayo MS, Phillips TA, et al. Reduction in proliferation with six 
months of letrozole in women on hormone replacement therapy. Breast Cancer Res Treat. 2007. 
22. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev 
Cancer. 2003;3:267-75. 
23. Gulmann C, Sheehan KM, Kay EW, Liotta LA, Petricoin EF, 3rd. Array-based proteomics: mapping of 
protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. J Pathol. 2006;208:595-606. 
24. Latta EK, Tjan S, Parkes RK, O'Malley FP. The role of HER2/neu overexpression/amplification in the 
progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol. 2002;15:1318-25. 
Proprietary Information of MD Anderson

33 
 
 
 
MDACC# 2010-0794 
 
 
Version Date: 6.13.17 
 
 
25. Schapira DV, Kumar NB, Lyman GH. Obesity, body fat distribution, and sex hormones in breast cancer 
patients. Cancer. 1991;67:2215-8. 
26. Fabian CJ, Kimler BF. Use of biomarkers for breast cancer risk assessment and prevention. J Steroid 
Biochem Mol Biol. 2007;106:31-9. 
Proprietary Information of MD Anderson